Back to Search Start Over

Standardized generation of human iPSC-derived hematopoietic organoids and macrophages utilizing a benchtop bioreactor platform under fully defined conditions.

Authors :
Ackermann, Mania
Saleh, Fawaz
Abdin, Shifaa M.
Rafiei Hashtchin, Anna
Gensch, Ingrid
Golgath, Julia
Carvalho Oliveira, Marco
Nguyen, Ariane H. H.
Gaedcke, Svenja
Fenske, Arno
Jang, Mi-Sun
Jirmo, Adan C.
Abeln, Markus
Hansen, Gesine
Lachmann, Nico
Source :
Stem Cell Research & Therapy. 6/18/2024, Vol. 15 Issue 1, p1-21. 21p.
Publication Year :
2024

Abstract

Background: There is a significant demand for intermediate-scale bioreactors in academic and industrial institutions to produce cells for various applications in drug screening and/or cell therapy. However, the application of these bioreactors in cultivating hiPSC-derived immune cells and other blood cells is noticeably lacking. To address this gap, we have developed a xeno-free and chemically defined intermediate-scale bioreactor platform, which allows for the generation of standardized human iPSC-derived hematopoietic organoids and subsequent continuous production of macrophages (iPSC-Mac). Methods: We describe a novel method for intermediate-scale immune cell manufacturing, specifically the continuous production of functionally and phenotypically relevant macrophages that are harvested on weekly basis for multiple weeks. Results: The continuous production of standardized human iPSC-derived macrophages (iPSC-Mac) from 3D hematopoietic organoids also termed hemanoids, is demonstrated. The hemanoids exhibit successive stage-specific embryonic development, recapitulating embryonic hematopoiesis. iPSC-Mac were efficiently and continuously produced from three different iPSC lines and exhibited a consistent and reproducible phenotype, as well as classical functionality and the ability to adapt towards pro- and anti-inflammatory activation stages. Single-cell transcriptomic analysis revealed high macrophage purity. Additionally, we show the ability to use the produced iPSC-Mac as a model for testing immunomodulatory drugs, exemplified by dexamethasone. Conclusions: The novel method demonstrates an easy-to-use intermediate-scale bioreactor platform that produces prime macrophages from human iPSCs. These macrophages are functionally active and require no downstream maturation steps, rendering them highly desirable for both therapeutic and non-therapeutic applications. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
17576512
Volume :
15
Issue :
1
Database :
Academic Search Index
Journal :
Stem Cell Research & Therapy
Publication Type :
Academic Journal
Accession number :
177950005
Full Text :
https://doi.org/10.1186/s13287-024-03785-2